" XORTX Therapeutics (TSXV:XTRX) reveals study of hospitalized COVID-19 patients

XORTX (XRTX) has shared studies from its article, “Prevalence and Outcomes Associated with Hyperuricemia in Hospitalized Patients with COVID-19”.
XORTX Therapeutics - CEO, Allen Davidoff.

" XORTX Therapeutics (CSE:XRX) to commence trading on the TSX Venture Exchange

XORTX Therapeutics (XRX) has received approval to list its common shares on the TSXV effective as of November 4, 2021.

" XORTX Therapeutics (CSE:XRX) closes public offering

XORTX Therapeutics (XRX) announced the closing of a US$12M public offering.

" Today’s market summary: energy shortages dampen economic recovery

On Wednesday, the TSX climbed to 20,618.47, its highest level since mid-September, as heightened U.S.
XORTX Therapeutics - CEO, Allen Davidoff.

" XORTX Therapeutics (CSE:XRX) announces Nasdaq listing and $12 million public offering

XORTX (XRX) begins trading today on the Nasdaq Capital Market in conjunction with a US$12 million public offering.
XORTX Therapeutics - CEO, Allen Davidoff.

" XORTX Therapeutics (CSE:XRX) granted European patent

XORTX Therapeutics (XRX) has been granted a European patent for the prevention and treatment of diabetic nephropathy.